propranolol has been researched along with a-484954 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodama, T; Okada, M; Yamawaki, H | 1 |
| Kameshima, S; Kodama, T; Okada, M; Otani, K; Yamawaki, H | 1 |
2 other study(ies) available for propranolol and a-484954
| Article | Year |
|---|---|
Eukaryotic elongation factor 2 kinase inhibitor, A484954 potentiates β-adrenergic receptor agonist-induced acute decrease in diastolic blood pressure in rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Pressure; Blood Pressure Determination; Cyclopropanes; Heart Rate; Male; Myocardial Contraction; Propranolol; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrrolidines; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Vasodilation | 2019 |
Eukaryotic elongation factor 2 kinase inhibitor, A484954 induces diuretic effect via renal vasorelaxation in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Disease Models, Animal; Diuretics; Elongation Factor 2 Kinase; Humans; Hypertension; Kidney; Male; Propranolol; Pyridines; Pyrimidines; Rats; Rats, Inbred SHR; Receptors, Adrenergic, beta; Renal Circulation; Vasodilation | 2021 |